Press release
Chronic Hepatitis B Virus FDA Approvals, Clinical Trials, Emerging Drugs and Pipeline Report 2024 (Updated)
Chronic Hepatitis B Virus Pipeline
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
• Over 50+ Chronic Hepatitis B Virus companies are evaluating 55+ Chronic Hepatitis B Virus pipeline therapies in various stages of development, and their anticipated acceptance in the Chronic Hepatitis B Virus market would significantly increase market revenue.
• The leading Chronic Hepatitis B Virus Companies working in the market include Vedanta Biosciences, Gilead Sciences, Dong-ASTCo, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, and others.
• Promising Chronic Hepatitis B Virus Pipeline Therapies in the various stages of development include BRII-835, Entecavir, EYP001a, Entecavir, RBD1016, ABI-H3733, LW231 tablets, and others.
• April 2024: Gilead Sciences announced a study of Phase 2 clinical trials for TAF. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
• April 2024: Ascletis Pharmaceuticals Co., Ltd. announced a study of Phase 2 clinical trials for ASC42 10mg and Entecavir. This is a phase2, randomized, single-blind, placebo controlled and multi-center study in adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety of ASC42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic hepatitis B virus.
Request a sample and discover the recent breakthroughs happening in the Chronic Hepatitis B Virus Pipeline landscape @ Chronic Hepatitis B Virus Pipeline Outlook Report- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Chronic Hepatitis B Virus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chronic Hepatitis B Virus NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Chronic Hepatitis B Virus Overview
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously.
Find out more about Chronic Hepatitis B Virus Therapeutics Assessment @ Chronic Hepatitis B Virus Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Chronic Hepatitis B Virus Emerging Therapies Profile
• Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand's HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.
• RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.
Chronic Hepatitis B Virus Therapeutics Assessment
There are approx. 50+ key Chronic Hepatitis B Virus companies which are developing the Chronic Hepatitis B Virus therapies. The Chronic Hepatitis B Virus companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Ligand Pharmaceuticals.
DelveInsight's Chronic Hepatitis B Virus pipeline report covers around 55+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Chronic Hepatitis B Virus Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Chronic Hepatitis B Virus Pipeline Therapies @ Chronic Hepatitis B Virus Clinical Trials Assessment- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Chronic Hepatitis B Virus Pipeline Report
• Coverage- Global
• Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-ASTCo, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, and others.
• Chronic Hepatitis B Virus Pipeline Therapies- BRII-835, Entecavir, EYP001a, Entecavir, RBD1016, ABI-H3733, LW231 tablets, and others.
• Chronic Hepatitis B Virus Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Chronic Hepatitis B Virus Pipeline Companies and Therapies, click here @ Chronic Hepatitis B Virus Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Chronic Hepatitis B Virus Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Hepatitis B Virus Infection - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Pradefovir: Ligand Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RG6346: Dicerna Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. VIR-3434: Vir Biotechnology
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. SBT8230: Silverback Therapeutics
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Chronic Hepatitis B Virus Infection Key Companies
24. Chronic Hepatitis B Virus Infection Key Products
25. Chronic Hepatitis B Virus Infection - Unmet Needs
26. Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
27. Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
28. Chronic Hepatitis B Virus Infection Analyst Views
29. Chronic Hepatitis B Virus Infection Key Companies
30. Appendix
Got Queries? Find out the related information on Chronic Hepatitis B Virus Mergers and acquisitions and chronic Hepatitis B Virus Licensing Activities @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Peripheral T-cell Lymphoma Market- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Retinitis Pigmentosa Market- https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/oropharyngeal-cancer-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Paranasal Sinus Cancer Market- https://www.delveinsight.com/report-store/paranasal-sinus-cancer-market
Castration-resistant Prostate Cancer Market- https://www.delveinsight.com/report-store/castration-resistant-prostate-cancer-crpc-market
Opioid Withdrawal Syndrome Market- https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Cervical Dystonia Market- https://www.delveinsight.com/report-store/cervical-dystonia-market
Schizophrenia Market- https://www.delveinsight.com/report-store/schizophrenia-market-insight
Focal Segmental Glomerulosclerosis Market- https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market
Obstructive Sleep Apnea Market- https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
Severe Hypertriglyceridemia Market- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
Short Bowel Syndrome Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Complement 3 Glomerulopathy Market- https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Aplastic Anemia Market- https://www.delveinsight.com/report-store/aplastic-anemia-market
Nephrotic Syndrome Market- https://www.delveinsight.com/report-store/nephrotic-syndrome-market
Pulmonary Arterial Hypertension Market- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
Hemophilia A Market- https://www.delveinsight.com/report-store/hemophilia-a2030-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus FDA Approvals, Clinical Trials, Emerging Drugs and Pipeline Report 2024 (Updated) here
News-ID: 3529219 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
Automatic Balancing Valves Market Research Report 2017: IMI Hydronic, Danfoss, F …
In this report, the global Automatic Balancing Valves market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Request for sample of Automatic Balancing Valves Market research report @ https://www.qyresearchgroups.com/request-sample/365951
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate…
